Fosamprenavir

Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430) . Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection[1][2].

Product Specifications

CAS Number

[226700-79-4]

Product Name Alternative

Amprenavir phosphate; GW 433908

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Drug Intermediate; HIV; HIV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Fosamprenavir.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O)(O)=O)CN(S(=O)(C3=CC=C(N)C=C3)=O)CC(C)C

Molecular Formula

C25H36N3O9PS

Molecular Weight

585.61

Precautions

H315, H319, H320

References & Citations

[2]Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1 (Suppl 1) :S1-S11.|[1]Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40 (7-8) :1301-10.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

HIV-1

Citation 01

Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Research Square Print. 2022 May.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.